Sunday, July 29, 2018

GSK Turns To Profit In Q2; Signs Deal With 23andMe On New Medicines

(RTTNews.com) - GlaxoSmithKline plc (GSK, GSK.L) reported that its profit attributable to shareholders for the second-quarter was 441 million pounds or 8.9 pence per share, compared to a loss of 180 million pounds or 3.7 pence per share in the prior year.

Read more... https://www.nasdaq.com/article/gsk-turns-to-profit-in-q2-signs-deal-with-23andme-on-new-medicines-20180725-00375